

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C08B 37/08, A61K 47/48		A1	(11) International Publication Number: WO 96/35721
			(43) International Publication Date: 14 November 1996 (14.11.96)
(21) International Application Number: PCT/EP96/01980 (22) International Filing Date: 8 May 1996 (08.05.96) (30) Priority Data: PD95A000089 10 May 1995 (10.05.95) IT (71) Applicant (for all designated States except US): FIDIA ADVANCED BIOPOLYMERS S.R.L. [IT/IT]; Via de' Carpentieri, 3, I-72100 Brindisi (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): KHAN, Riaz [GB/GB]; "Rumsey" Old Bath Road, Sonning, Berkshire RG4 6TA (GB). KONOWICZ, A., Paul [US/GB]; 12 Ambleside Crescent, Folly Hill, Farnham, Surrey GU9 0R2 (GB). (74) Agent: COGGI, Giorgio; Notarbartolo & Gervasi S.r.l., Viale Bianca Maria, 33, I-20122 Milano (IT).		(81) Designated States: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(54) Title: A DICARBOXYLIC ACID HEMIESTER OR HEMIAMIDE WITH A PHARMACOLOGICALLY ACTIVE COMPOUND AND WITH HYALURONIC ACID OR WITH A HYALURONIC ACID ESTER, A PROCESS FOR ITS PREPARATION AND A CONTROLLED RELEASE MEDICAMENT CONTAINING THIS DERIVATIVE (57) Abstract A dicarboxylic acid hemiester or hemiamide with a pharmacologically active compound and with hyaluronic acid or a hyaluronic total or partial ester, a process for its preparation and relative controlled release medicaments containing this hemiester or hemiamide.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

- 1 -

A DICARBOXYLIC ACID HEMIESTER OR HEMIAMIDE WITH A PHARMACOLOGICALLY ACTIVE COMPOUND AND WITH HYALURONIC ACID OR WITH A HYALURONIC ACID ESTER, A PROCESS FOR ITS PREPARATION AND A CONTROLLED RELEASE MEDICAMENT CONTAINING THIS DERIVATIVE.

5 **FIELD OF THE INVENTION**

The present invention relates to a hemiester or a hemiamide of a dicarboxylic acid with a pharmacologically active compound and with hyaluronic acid or a hyaluronic acid total or partial ester and the relative controlled release medicament containing this derivative.

10 **TECHNOLOGICAL BACKGROUND**

Hyaluronic acid is a linear polysaccharide, whose structure is constituted by alternate units of 1,4- β -D-glucuronic acid and 1,3- β -N-acetyl-D-glucosamine.

15 Hyaluronic acid is a fundamental component of the connective tissue of animals as it is present, for example, in the skin and cartilage. It is also found in greater quantities in the synovial fluid, in the vitreous humor of the eye and in the umbilical cord. The main sources of commercially available hyaluronic acid at present are cockscombs and the vitreous humor. The biotechnological production of hyaluronic
20 acid from Streptococcus cultures is becoming increasingly important. Being a fundamental component of the connective tissue, hyaluronic acid is biocompatible, bioabsorbable and not immunogenic, and it therefore plays a crucial role in many biological functions such as tissue hydration; proteoglycan organization in the cartilage, tissue
25 repair, embryonic development, as well as the lubrication and

- 2 -

protection of the joint cartilage. This polysaccharide is currently used in the treatment of some joint diseases such as rheumatoid arthritis. It is also used in the practice known as microviscosurgery, in particular in surgery to the eye. When used in this field, its rheological characteristics are exploited as well as the biocompatibility of high-molecular weight hyaluronic acid. Its biological functions are closely linked with its molecular weight as they depend on the viscoelastic and rheological properties which the polymer lends to solutions (T. C. Laurent et al., The Faseb Journal, 6: 2397-2404, 1992).

Lastly, considering its excellent characteristics of biocompatibility, hyaluronic acid represents the preferred carrier in which biologically active molecules can be incorporated in controlled release systems. The properties of this material and the environmental factors determine the release rate of the active molecule.

Controlled release systems for drugs have aroused a great deal of interest in the scientific world due to their enormous applicative potential. Of the various sectors in which they can be used, the pharmaceutical field is one of the most important, and one in which such systems must needs be constantly improved to ensure optimum diffusion of the drug in the desired application site. Generally, most of these slow release systems consist of a physical mixture of active compound and suitable polymer matrix. Different kinds of controlled release formulations are, however, now coming to light, in which the drug is covalently linked to the matrix and the release rate is, in this case, modulated by the hydrolysis rate of the chemical link between the polymer and the drug.

- 3 -

Polymers such as starch are already known to the state of the art and are used as matrices to link drugs (Ferrati et al., Macromol. Chem. 180: 375-380, 1979). For example, the treatment of succinic esters of starch with 4-aminobenzoic acid or with L-DOPA (3,4-
5 dihydroxyphenylalanine) in N,N-dimethylformamide or dimethylsulfoxide in the presence of imidazole and N,N-dicyclohexylcarbodiimide, gives a polymer derivative wherein the drug is covalently linked to the starch matrix by means of a succinate group (P. Ferrati et al., Macromol. Chem., 180 (1979) 375-380). There are, however, no known compounds of
10 this type wherein the polysaccharide is hyaluronic acid, although there are some known systems constituted by hyaluronic acid derivatives to which the drug is chemically linked (US 4,851,521) by means of the carboxylic function of hyaluronic acid.


DESCRIPTION OF THE INVENTION

15 The present invention describes derivatives wherein the drug is not directly linked to the polysaccharide but is chemically reacted with a "spacer arm" before being linked to the polysaccharide. In the cases reported in the literature the position on which the substitution reaction took place was the acid group of the glucuronic residue of
20 the repetitive unit, but in the derivatives of the present invention a reaction has been devised, whereby the positions subject to substitution are constituted by the free hydroxyl functions of the two glucuronic acid and N-acetylglucosamine residues of the repetitive unit.

25 A subject of the present invention therefore relates to a dicarboxylic acid hemiester or hemiamide with a pharmacologically active compound and with hyaluronic acid or a hyaluronic acid partial

- 4 -

or total ester having the following repeating unit (I):



(I)

wherein R = OH, an alcoholic residue or O^-Na^+ , $R^1 = H$ or $-CO(CH_2)_n-$
 COR^2 , wherein n is an integer ranging from 1 to 10, and R^2 is an
 alcoholic or an aminic residue of said pharmacologically active
 5 compound.

In the hemiester, subject of the present invention hyaluronic acid can
 be linked to a greater quantity of drug by the introduction of a
 "spacer arm", constituted by the dicarboxylic acid.

Hyaluronic acid was chosen from among the various biocompatible
 10 polysaccharides available, because of its particularly interesting
 properties. As we have said, its presence in various body compartments
 makes it far more suitable than other polysaccharides for the
 development of new drug matrices. Lastly, it should also be remembered
 that hyaluronic acid has proved therapeutically efficacious as an
 15 agent in reepithelialization, in tissue repair and in the recovery of
 normal conditions in joints affected by processes of an arthritic
 type. The use of this polymer as a matrix for drug release, apart from


- 5 -

guaranteeing the biocompatibility of the formulation, enables the intrinsic activity of hyaluronic acid to be associated with the therapeutic efficacy of the drug linked to it.


The hyaluronic acid esters used for preparing the dicarboxylic acid hemiester or hemiamide according to the present invention are the total or partial esters with an alcohol of the aliphatic or cycloaliphatic series, which do not themselves possess a notable pharmacological action and are disclosed in USP 4,851,521, which we incorporate herewith by reference.

A further subject of the present invention consists in the process for preparing the dicarboxylic hemiester according to the present invention which in particular comprises the following steps:

a) reacting the dicarboxylic acid anhydride of formula (II)




wherein n has the aforementioned meanings with stoichiometric amounts of the pharmacologically active compound of formula R^2H wherein R^2 has the above mentioned meanings in the presence of a hydrogen ion acceptor, thereby obtaining the hemiester or the hemiamide of the dicarboxylic acid with the pharmacologically active compound (III)



- 6 -

b) reacting the intermediate (III) coming from the preceding step with a chlorinating agent in an apolar aprotic solvent, in the presence of a catalytic amount of dimethylformamide, thereby obtaining the corresponding acyl chloride (IV):



(IV)

5 c) reacting the intermediate (IV) with one of the following hyaluronic acid derivatives:


i) a salt of hyaluronic acid, whose cation is selected from: pyridinium, tetraalkylammonium, tetraarylammonium, tetraalkylphosphonium, tetraarylphosphonium,

10 ii) a salt of a hyaluronic acid partial ester, whose cation is selected from: pyridinium, tetraalkylammonium, tetraaryl- ammonium, tetraalkylphosphonium, tetraarylphosphonium,

iii) a hyaluronic acid total ester.

15 in the presence of an aprotic solvent and an organic base as the catalyst, thereby obtaining:

the dicarboxylic acid hemiester with said pharmacologically active compound and with the salt of hyaluronic acid or a hyaluronic acid partial ester having the repeating unit (I-A)



- 7 -

wherein R' is an alcoholic residue or O^- . Y^+ , wherein Y^+ is selected from the group consisting of pyridinium, tetraalkylammonium, tetraarylammonium, tetraalkylphosphonium, tetraarylphosphonium, provided that in at least one of said repeating units R' is $= O^-$. Y^+ .

5 or obtaining the dicarboxylic acid hemiester with said pharmacologically active substance and a hyaluronic acid total ester having the repeating unit (I) wherein R is an alcoholic residue,
d) converting by dialysis the intermediate having the repeating unit (I-A) and coming from the preceding step into the corresponding
10 dicarboxylic acid hemiester or hemiamide having the repeating unit (I) wherein, in at least one repeating (I), R is OH or O^-Na^+ .

e) recovering the desired product having the repeating unit (I) coming from the preceding step or from step (c), by freeze drying or by crystallization in an ether solvent, filtration of the desired
15 product and successive vacuum drying. A further subject of the present invention is a controlled release medicament containing the hemiester or hemiamide according to the present invention.

DETAILED DESCRIPTION OF THE INVENTION

In the hemiester or hemiamide according to the present invention, when
20 R in the repeating unit (I) is an alcoholic residue, it is preferably the residue of benzyl alcohol.


The preferred dicarboxylic acid derivatives according to the present invention are in any case the hemiesters, namely the compounds, whose repeating unit (I) has $R^2 =$ an alcoholic residue of a
25 pharmacologically active substance and n is preferably comprised between 2 and 4, in other words the hemiester according to the present invention comes from a dicarboxylic acid selected from the group

- 8 -

consisting of succinic, glutaric, and adipic acid.

Particularly preferred hemiesters according to the present invention are the succinic acid hemiesters of active substances selected from the group consisting of propofol, methyl-prednisolone (prednisone) and
5 cholesterol.

Therefore particularly preferred hemiesters according to the present invention are those whose repeating unit (I) has $R^1 = H$ or $CO(CH_2)_2-COR_2$ wherein R_2 is selected from



For example in the hemiester according to the present invention, when
10 R_2 is an alcoholic residue of prednisone, hyaluronic acid is not only interesting because of its biocompatibility and bioabsorbability, but also because of its own therapeutic efficacy. In particular, the advantage of using this type of polysaccharide, substituted by a
15 spacer arm, with compounds with antiinflammatory activity, is represented by the possibility of having slow release of the drug and of obtaining a synergic effect of the two components after hydrolysis

- 9 -

of the bond. Indeed, both hyaluronic acid and steroid-type antiinflammatory drugs (such as methylprednisolone) have proved to be efficacious in reducing symptoms associated with osteoarthritis of the knee (G. Leardini et al., *Clinical and Experimental Rheumatology*, 9 (1991) 375-381). Alkyl and aryl esters of hyaluronic acid have been used in preparations containing methylprednisolone, both as polymer matrices in the form of microspheres wherein the drug is physically incorporated, and as substrates on which methylprednisolone is chemically linked (K. Kyyrönen et al., *Int. J. Pharmaceutics*, 80, (1992), 161-169; L. Benedetti et al., *New Polymer Material*, 3 (1991) 41-48).

Another example of a biologically interesting molecule that has been covalently linked to hyaluronic acid by means of a spacer arm according to the present invention is represented by an antioxidant compound bearing a phenol group, i.e. the above mentioned Propofol (2,6-diisopropylphenol). In this case too, the introduction of propofol in pharmaceutical preparations containing hyaluronic acid has proved interesting, considering its activity. Indeed, the superoxide radical (O_2^-) generated by enzymatic processes can depolymerize hyaluronic acid (J. M. McCord, "Free radicals and inflammation. Protection of synovial fluid by superoxide dismutase", *Science*, 185, (1974) 529-531) thus reducing the lubricating, protective and shock absorbing properties of the synovial fluid. Phagocytosis by polymorphonucleate leukocytes produces superoxide radicals which can then constitute one of the mechanisms of degradation of the synovial fluid *in vivo* in inflammatory situations of the joints. It has been demonstrated that many antiinflammatory drugs and free radical

- 10 -

scavengers are efficacious in protecting hyaluronic acid from depolymerization by radicals (P. Puig-Parellada et al., *Biochem. Pharmacology*, 27, (1978) 535-537; C. Parenti et al., *Pharmazie*, 45 (1990) 680-681).

5 Propofol is an anaesthetic for intravenous administration whose efficacy as a free radical scavenger is due to its ability to form stable radicals. Indeed, its efficacy as a scavenger for hydroxy radicals generated by xanthine oxidase/hypoxanthine has been demonstrated by assessing *in vitro* the depolymerization of hyaluronic
10 acid in artificial synovial fluid (C. Kvam et al., *Biochem. Biophys Res. Commun.*, 193 (1993) 927-933). For this reason, Propofol has been proposed as a possible shield for hyaluronic acid. The use of the succinic group as a spacer arm proves to be particularly important in this case because the formation of a direct ester bond between the
15 phenol group and the carboxyl group of the polymer is particularly difficult due to steric hindrance.

In the process according to the present invention for preparing the above mentioned preferred succinic acid hemiesters having the repeating unit (I) wherein R_2 is an alcoholic residue of prednisone,
20 propofol, cholesterol or any other molecule with an alcoholic residue step (a) is carried out by reacting succinic anhydride in the presence of an organic base such as pyridine as the hydrogen ion acceptor, to obtain the corresponding hemiester (II). In step (b) the chlorinating agent used to transform the hemiester into the
25 corresponding chloride acyl can be any chlorinating reagent such as thionyl chloride or sulfuryl chloride. In this case we used oxalyl chloride in methylene chloride in the presence of catalytic quantities

- 11 -

of N,N-dimethylformamide.

Step (c) is preferably carried out by using dimethylformamide as the solvent and by using as the catalyst pyridine, 4 dimethyl amino pyridine or a mixture thereof .

- 5 To prepare the hemiester according to the present invention with antiinflammatory drugs, hyaluronic acid and the alkyl and the partial or total esters thereof, of any molecular weight, can be used. The following examples were prepared using samples of hyaluronic acid with molecular weights ranging from 30,000 to 760,000.
- 10 The succinyl derivatives of hyaluronic acid or the esters thereof conjugated with drugs such as prednisone, propofol and cholesterol etc. described in the present invention can, therefore, be used to advantage directly or in pharmaceutical formulations for the treatment of various forms of arthritis and joint inflammations.
- 15 The above-mentioned compounds constitute a probable substrate for the action of the lipases in the human body and in one case supply hyaluronic acid, succinic acid and the drug, and in the case of benzyl derivatives of hyaluronic acid they supply hyaluronic acid, benzyl alcohol, succinic acid and the drug.
- 20 For purely illustrative purposes we report hereafter some examples of the preparation of succinyl derivatives of hyaluronic acid or of its esters, covalently linked to biologically active molecules:

Example 1

Preparation of hemisuccinate propofol

- 25 A solution of Propofol (10 mL, 54 mmol) in pyridine (25 mL) was supplemented with succinic anhydride (4.86 g, 48.6 mmol) while being stirred at 70°C for 96 hours. The solution was then concentrated in

- 12 -

conditions of reduced pressure until a syrup was obtained. The residue was chromatographed on a silica gel column using diethyl ether and petroleum ether (low-boiling fraction) (2:3), after crystallization from diethyl ether to petroleum ether had given the hemisuccinate propofol compound (7.0 g), melting point 101-102°C.

The ^{13}C n.m.r. spectrum of the product in DMSO-d_6 (50.3 MHz) presents the following signals: δ 179.8 (COOH), 171 (C=O), 145.63, 140.54, 126.79, 124.11 (aromatic carbons), 28.04, 28.83 (CH_2), 27.64 (CH), 23.38 (CH_3).

10 The spectrum of the proton in DMSO-d_6 presents the following signals: δ 1.21, 1.23, (CH_3), 2.71-3.0 (CH_2 , CH), 7.12-7.27 (aromatic protons).

Preparation of propofol-succinyl-hyaluronate

Hyaluronic acid (MW 30,000, 100 mg) was dissolved in distilled water (25 mL) and the pH was brought to approximately 2.5 using an ion exchange resin (IRA 120 H^+). The resin was then removed by filtration and the solution concentrated to about 10 mL. 50 mL of N,N-dimethylformamide (DMF) were then added and the solution was concentrated to about 20 mL. This procedure was repeated three times to substitute most of the water with DMF. The solution was then neutralized with an excess of pyridine (5 mL) to give a solution with a gel-like consistency that was then treated with a solution of propofol succinyl chloride [prepared from hemisuccinate propofol (36 mg, 0.14 mmol), DMF (1 drop), oxalyl chloride (120 μL , 0.14 mmol) in anhydrous methylene chloride (3 mL) for 1 hour] and shaken at room temperature for 24 hours. The reaction mixture was then dialyzed against distilled water (6 times 1 L). The resulting solution (opalescent) was freeze-dried to give propofol-succinyl-hyaluronate in

- 13 -

the form of white flakes (72 mg).

The product has limited solubility in water. The n.m.r. spectra of ^1H and ^{13}C show the presence of signals due to the protons and carbons of the succinic group. The spectrum confirms the presence of protons of an aromatic type. The degree of substitution based on qualitative n.m.r. results is 11-15%.

Hyaluronic acid (MW 30,000, 250 mg) was dissolved in distilled water (50 mL) and the pH was brought to approximately 2.5, using an ion exchange resin (IRA 120 H^+). The resin was then removed by filtration and the solution was concentrated to about 10 mL. 50 mL of N,N-dimethylformamide (DMF) were then added and the solution was concentrated to about 20 mL. This procedure was repeated three times to substitute most of the water with DMF. The solution was then neutralized with an excess of pyridine (5 mL) to give a solution with a gel-like consistency which was then treated with a solution of propofol succinyl chloride [prepared from hemisuccinate propofol (90 mg), DMF (1 drop), oxalyl chloride (300 μL) in anhydrous methylene chloride (7.5 mL)] and shaken at room temperature for 24 hours. The product was then precipitated with ether, washed with methylene chloride to remove all the reagents and vacuum-dried for 24 hours to give propofol-succinyl-hyaluronate (250 mg).

Table 1 reports the sample's chemical shifts in DMSO. In all the tables reporting n.m.r. data, G indicates the glucuronic acid residue of hyaluronic acid (eg, G-1 indicates the anomeric carbon of glucuronic acid), N represents the glucosamine residue (eg, N-6 indicates carbon 6 of the glucosamine residue).

- 14 -

- TABLE 1 -

Chemical shift δ ppm	non-modified HA	modified HA	other groups
101.66	N-1		
55.45	N-2		
84.10	N-3		
69.99	N-4		
76.30	N-5		
62.02	N-6		
23.88	N-Ac		
104.20	G-1		
73.67	G-2		
75.04	G-3		
81.99	G-4		
76.93	G-5		
172.90	G-6		
175.07	N=C=O		
99.10		N-1	
54.05		N-2	
82.28		N-3	
63.30		N-6	
22.92		N-Ac	
71.74		G-2	
28.52			succinic CH ₂
172.03			succinic C=O
22.94, 26.71			CH ₃ , CH
			propofol
123.66, 126.23			Aromatic carbons

- 15 -

The degree of substitution calculated according to the esterification in N-6 was estimated at about 100%.

Example 2

Preparation of the propofol-succinyl derivative of the hyaluronic acid

5 **benzyl ester (HABE)**

A suspension of HABE (MW 140,000, 250 mg) in N,N-dimethylformamide (DMF, 16 mL) was stirred at room temperature for 0.5 hours, after which were added: pyridine (5 mL), 4-dimethylaminopyridine (20 mg) and a solution of propofol succinyl chloride [prepared from hemisuccinate
10 propofol (410 mg), DMF (2 drops), oxalyl chloride (130 µL) in ether (3 mL)]. The mixture was stirred at room temperature for 24 hours. The product was then precipitated from ether, repeatedly washed with methylene chloride to remove all the reagents used and then vacuum-dried to give the propofol succinyl derivative of the hyaluronic acid
15 benzyl ester (250 mg).

Table 2 reports the chemical shift values for the sample in DMSO.

- 16 -

- TABLE 2-

Chemical shift δ ppm	non-modified HA	modified HA	other groups
101.45	N-1		
59.90	N-2		
83.51	N-3		
68.86	N-4		
76.31	N-5		
60.93	N-6		
22.94	N-Ac		
102.68	G-1		
72.60	G-2		
73.52	G-3		
80.10	G-4		
79.113	G-5		
167.29	G-6		
169.58	N=C=O		
100.16		N-1	
59.40		N-2	
81.99		N-3	
68.86		N-4	
73.18		N-5	
63.51		N-6	
79.66		G-4	
28.96			succinic CH ₂
171.52, 170.78			succinic C=O
22.99, 26.72			CH ₃ , CH
			Propofol
123.66, 126.23			Aromatic carbons

- 17 -

It was possible to estimate the degree of substitution from the n.m.r. spectrum, according to the integration relative to carbon N-6, which was 45%.

Example 3

5 Synthesis of hemisuccinate cholesterol

A solution of cholesterol (7.5 g, 19.4 mmol) in pyridine (20 ml) was supplemented with succinic anhydride (2.04 g, 20.4 mmol) and the mixture was stirred at 60°C for 48 hours. The solution was then concentrated at reduced pressure to give, after crystallization from
10 butane-2-one, hemisuccinate cholesterol (6.62 g).

Preparation of cholesterol-succinyl-hyaluronate

Hyaluronic acid (MW 30.000, 500 mg) was dissolved in distilled water (125 mL) and the pH was brought to approximately 2.5 using an ion exchange resin (IRA 120 H⁺). The resin was then removed by filtration
15 and the solution was concentrated to about 45 mL. 100 mL of N,N-dimethylformamide (DMF) were then added and the solution was concentrated to about 50 mL. This procedure was repeated three times to substitute most of the water with DMF. The solution was then neutralized with an excess of pyridine (17 mL) to give a solution with
20 a gel-like consistency which was then treated with a solution of cholesterol succinyl chloride [prepared from hemisuccinate cholesterol (2.68 g, 5.5 mmol), DMF (1 drop), oxalyl chloride (0.51 mL, 5.8 mmol) in anhydrous methylene chloride (8 mL)] and stirred at room temperature for 24 hours. The reaction mixture was then dialyzed
25 against distilled water to give a water-soluble fraction which was then freeze-dried (230 mg) and a water-insoluble fraction which was vacuum-dried in the presence of phosphoric anhydride to give

- 18 -

cholesterolsuccinyl-hyaluronate (1.5 g).

The water-soluble derivative is characterized by a lower degree of modification with cholesterol-succinate than that of the water-insoluble fraction.

5 Example 4

Preparation of the cholesterol-succinyl derivative of hyaluronic acid benzyl ester (HABE)

A suspension of HABE (MW 140,000, 500 mg) in N,N-dimethylformamide (DMF, 16 mL) was stirred at room temperature for 0.5 hours and then
10 supplemented with: pyridine (4 mL), 4-dimethylaminopyridine (5 mg) and a solution of cholesterol succinyl chloride [prepared from hemisuccinate cholesterol (1.04 g, 4.29 mmol), DMF (2 drops), oxalyl chloride (0.392 mL, 45 mmol) in ether (9 mL)]. The mixture was stirred at room temperature for 24 hours. The reaction mixture was
15 concentrated to about half the original volume and the product was precipitated from ether, gathered with ethanol to give cholesterol-succinyl-HABE in the form of a solid product (550 mg).

Table 3 reports the assignment of ^{13}C -n.m.r. signals of cholesterol-succinylHABE.

- 19 -

- TABLE 3 -

Chemical shift δ ppm	non-modified HA	modified HA	other groups
100.45	N-1		
59.90	N-2		
83.51	N-3		
68.86	N-4		
76.31	N-5		
60.93	N-6		
22.94	N-Ac		
102.68	G-1		
72.60	G-2		
73.52	G-3		
80.10	G-4		
79.11	G-5		
167.29	G-6		
169.58	N=C=O		
100.00		N-1	
82.00		N-3	
63.40		N-6	
79.55		G-4	
28.70			succinic CH ₂
171.55, 170.02			succinic C=O
11.57 -49.5			CH ₃ , CH ₂ , CH
			cholesterol
121.87, 139.47			Aromatic
			carbons of
			benzyl group

- 20 -

Example 5

Preparation of hemisuccinate prednisone

A solution of prednisone (750 mg, 2.1 mmol) in anhydrous pyridine (10 ml) is supplemented with succinic anhydride (314 mg, 3.14 mmol) while stirring the mixture at 60°C for 96 hours. The solution is then concentrated at reduced pressure, the residue is dissolved in methylene chloride and then placed in a silica gel column and vacuum-dried. Silica gel chromatography using methylene chloride - petroleum ether (2:1) gives hemisuccinate prednisone (650 mg).

10 Preparation of prednisone succinyl hyaluronate

Hyaluronic acid (MW 30,000, 500 mg) was dissolved in distilled water (125 mL) and the pH was brought to approximately 2.5 using an ion exchange resin (IRA 120 H⁺). The resin was then removed by filtration and the solution concentrated to about 45 mL. 100 mL of N,N-dimethylformamide (DMF) were added and the solution was concentrated to about 50 mL. This procedure was repeated three times to substitute most of the water with DMF. The solution was then neutralized with an excess of pyridine (17 mL) to give a solution with a gel-like consistency which was then treated with a solution of prednisone succinyl chloride [prepared from hemisuccinate prednisone (280 mg, 0.58 mmol), by partially dissolving it in chloroform (3 mL) and dioxane (8 mL) and DMF (1 drop), and then adding oxalyl chloride (0.51 mL, 5.8 mmol) and stirring for 1 hour] and stirred at room temperature for 18 hours. The solution was concentrated to 20 mL, gathered with warm water (50°C) and then dialyzed against distilled water (6 times, 1 L). The prednisone-succinyl-hyaluronate was then recovered by freeze-drying (350 mg).

- 21 -

Table 4 shows the assignment of the ^{13}C -n.m.r. spectrum in $\text{DMSO:D}_2\text{O}$ (1:15) of the prednisone succinyl hyaluronate.

- TABLE 4 -

Chemical shift δ ppm	non-modified HA	modified HA	other groups
101.66	N-1		
55.45	N-2		
84.10	N-3		
69.99	N-4		
76.30	N-5		
62.02	N-6		
23.88	N-Ac		
104.20	G-1		
73.67	G-2		
75.04	G-3		
81.99	G-4		
76.93	G-5		
172.90	G-6		
175.07	N=C=O		
63.50		N-6	
29.77			succinic CH_2
159.43			prednisone CO
11.58 -68.40			CH_3 . CH_2 . CH of prednisone

- 22 -

N.m.r. data show the degree of substitution of the succinyl prednisone on the polymer to be about 5%.

Example 6

Preparation of the succinyl prednisone derivative of the hyaluronic
5 acid benzyl ester (HABE)

A suspension of HABE (MW 140,000, 100 mg) in N,N-dimethylformamide (DMF, 16 mL) was stirred at room temperature for 0.5 hours and then supplemented with: pyridine (4 mL), 4-dimethylaminopyridine (5 mg) and a solution of prednisone succinyl chloride [prepared from
10 hemisuccinate prednisone (170 mg), DMF (2 drops), oxalyl chloride (34 μ L) in ether (5 mL)]. The mixture was stirred at room temperature for 24 hours. The reaction mixture was concentrated to about half its original volume and the product was then precipitated from ether, gathered with ethanol and stirred for 0.5 hours to give prednisone-
15 succinyl-HABE (120 mg).

Table 5 shows the assignment of the ^{13}C -n.m.r. spectrum of the prednisone succinyl-HABE.

- 23 -

- TABLE 5 -


Chemical shift δ ppm	non-modified HA	modified HA	other groups
100.45	N-1		
59.90	N-2		
83.51	N-3		
68.86	N-4		
76.31	N-5		
60.93	N-6		
22.99	N-Ac		
102.68	G-1		
72.60	G-2		
73.52	G-3		
80.10	G-4		
79.11	G-5		
167.29	G-6		
169.58	N=C=O		
22.89		N-Ac	
82.00		N-3	
63.50		N-6	
79.70		G-4	
171.35, 166.63			succinic CH ₂
154.80			CO prednisone
14.93, 49.38			CH ₃ , CH ₂ , CH
59.18, 67.71			prednisone
123.69, 135.33			Aromatic
			carbons of
			benzyl group

¹³C-n.m.r. data show the degree of substitution of the polymer with succinyl prednisone to be about 10%.

- 24 -


CLAIMS

1. A dicarboxylic acid hemiester or hemiamide with a pharmacologically active compound and with hyaluronic acid or a hyaluronic acid partial or total ester having the following repeating unit (I):




(I)


- wherein R = OH, an alcoholic residue or O^-Na^+ , $R^1 = H$ or $-CO(CH_2)_n-$ COR^2 , wherein n is an integer ranging from 1 to 10, and R^2 is an alcoholic or an aminic residue of said pharmacologically active compound.
2. The dicarboxylic acid hemiester or hemiamide according to claim 1 wherein, when R in the repeating unit (I) is an alcoholic residue, it is the residue of benzyl alcohol.
3. The dicarboxylic acid hemiester according to one of the claims 1 or 2, whose repeating unit (I) has $R^2 =$ an alcoholic residue of a pharmacologically active substance and n is comprised between 2 and 4.
4. The dicarboxylic acid hemiester according to one of the claims 1, 2, 3 whose repeating unit (I) has $R^1 = H$ or $CO(CH_2)_2-COR_2$ wherein R_2 is selected from the group consisting of:



- 1 5. A process for preparing the dicarboxylic hemiester or hemiamide
 2 according to one of the claims 1-3, comprising the following steps:
 3 a) reacting the dicarboxylic acid anhydride of formula (II):




- 4 wherein n has the aforementioned meanings with stoichiometric amounts
 5 of the pharmacologically active compound of formula R^2H wherein R^2 has
 6 the above mentioned meanings in the presence of a hydrogen ion
 7 acceptor, thereby obtaining the hemiester or the hemiamide of the
 8 dicarboxylic acid with the pharmacologically active compound (III)



- 26 -

9 b) reacting the intermediate (III) coming from the preceding step with
10 a chlorinating agent in an apolar aprotic solvent, in the presence of
11 a catalytic amount of dimethylformamide, thereby obtaining the
12 corresponding acyl chloride (IV):



(IV)

13 c) reacting the intermediate (IV) with one of the following hyaluronic
14 acid derivatives:

15 i) a salt of hyaluronic acid, whose cation is selected from the
16 group consisting of: pyridinium, tetraalkylammonium,
17 tetraarylammonium, tetraalkylphosphonium, tetraarylphosphonium


18 ii) a salt of a hyaluronic acid partial ester, whose cation is
19 selected from the group consisting of: pyridinium, tetra-
20 alkylammonium, tetraarylammonium, tetraalkylphosphonium,
21 tetraarylphosphonium

22 iii) a hyaluronic acid total ester,

23 in the presence of an aprotic solvent and an organic base as the
24 catalyst, thereby obtaining:

25 the dicarboxylic acid hemiester with said pharmacologically active
26 compound and with the salt of hyaluronic acid or a hyaluronic acid
27 partial ester having the repeating unit (I-A)

- 27 -



(I-A)

28 wherein R' is an alcoholic residue or O⁻. Y⁺ wherein Y⁺ is selected
 29 from the group consisting of pyridinium, tetraalkylammonium,
 30 tetraarylammonium, tetraalkylphosphonium, tetraarylphosphonium
 31 provided that in at least one of said repeating units R' is = O⁻. Y⁺,
 32 or obtaining

33 the dicarboxylic acid hemiester with said pharmacologically active
 34 substance and a hyaluronic acid total ester having the repeating unit
 35 (I) wherein R is an alcoholic residue,

36 d) converting by dialysis the intermediate having the repeating unit
 37 (I-A) and coming from the preceding step into the corresponding
 38 dicarboxylic acid hemiester or hemiamide having the repeating unit
 39 (I), wherein, in at least one repeating unit (I), R is OH or O⁻Na⁺,

40 e) recovering the desired product coming from the preceding step or
 41 from step (c), by freeze drying, or by crystallization carried out in
 42 the presence of an ether solvent, filtration of the desired product
 43 and successive vacuum drying.

1 6. The process according to claim 5 for preparing the succinic acid
 2 hemiesters according to claim 4, wherein step (a) is carried out by

- 28 -

3 reacting succinic anhydride in the presence of pyridine as the
4 hydrogen ion acceptor, to obtain the corresponding hemiester (II) and
5 by using as the chlorinating agent oxalyl chloride.

1 7. A process according to one of claims 5 and 6 wherein step (c) is
2 carried out by using an organic base, as the catalyst, selected from
3 the group consisting of pyridine, 4-dimethyl amino pyridine and a
4 mixture thereof.

1 8. A controlled release medicament comprising the dicarboxylic acid
2 hemiester or hemiamide according to one of the claims 1-4.

1 9. A controlled release medicament according to claim 8 containing the
2 succinic acid hemiester according to claim 4 for the treatment of
3 osteoarticular joint diseases.

INTERNATIONAL SEARCH REPORT

International Application No

PC1/EP 96/01980

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C08B37/08 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C08B A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	PATENT ABSTRACTS OF JAPAN vol. 17, no. 339 (C-1075), 28 June 1993 & JP,A,05 039306 (D D S KENKYUSHUKO), 19 February 1993, see abstract ---	1-9
Y	EP,A,0 540 751 (EISAI CO.) 12 May 1993 see examples 1-5 ---	1-9
Y	PATENT ABSTRACTS OF JAPAN vol. 18, no. 222 (C-1193), 21 April 1994 & JP,A,06 016702 (SHISEIDO CO LTD), 25 January 1994, see abstract ---	1-9
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

18 September 1996

Date of mailing of the international search report

02.10.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Lensen, H

INTERNATIONAL SEARCH REPORT

International Application No

PL 1/EP 96/01980

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>INTERNATIONAL JOURNAL OF PHARMACEUTICS , vol. 80, 1992, pages 161-169, XP000600705 L. KYRÖNEN ET AL.: "Methylprednisolone esters of hyaluronic acid in ophthalmic drug delivery : in vitro and in vivo release studies." cited in the application see page 162, left-hand column, paragraph 2</p> <p>-----</p>	

...information on patent family members

PC 1/EP 96/01980

Form PCT/ISA/210 (patent family annex) (July 1992)